
Stock·NASDAQ·Consumer Cyclical
DraftKings Inc. (DKNG)
- Market cap
- $10.19B
- Dividend yield
- 0.00%
- Street target
- $31.00median of 37 analysts
- 52-week range
- $18.35 $36.98
The short version
Where DKNG stands today, and what CleaRank Financial AI makes of it.
DKNG at a glance
DraftKings Inc. (DKNG): Sell, 27/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($22.49 and $24.74).
- Insiders Insiders sold $86.8M and bought $3.2M over the last 18 months.
Figures as of October 22, 2026.
CleaRank Financial AI
CleaRank rates DraftKings Inc. (DKNG) Sell, with a model score of 27/100.
The analysts' outlook lifts the score most: 31 of 37 analysts rate it a buy and the median target is 51.0% above the price. The trend holds it back most: the price is 17.01% below its 200-day average and 8.70% below its 50-day average, and the 50-day average is 9.10% below the 200-day. The 50-day average stands at $22.49 and the 200-day at $24.74. Over the past year the price fell 38.94%.
Only on CleaRank
Figures we compute ourselves from DKNG's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $20.53 is 8.7% below the 50-day simple moving average of $22.49.Price above its 200-day average ›
The price is 17.0% below the 200-day simple moving average of $24.74.50-day average above the 200-day ›
The 50-day average ($22.49) is 9.1% below the 200-day average ($24.74), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 12% of its 52-week range, between $18.35 and $36.98.
DKNG share price
Pick a period: each tab shows how far DKNG has moved over it, to the last close.
Today's trading
Where DKNG sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
1/2P/S below the sector median ›
The price-to-sales ratio of 1.58 is 17.0% below the sector median of 1.9.Profitable over the last 12 months ›
Net income over the last 12 months was $-166.9M on revenue of $6.2B, a net margin of -2.7%.
Key statistics
The headline figures for DKNG.
As of October 22, 2026, DKNG trades at $20.53, with a market value of $10.19B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of DKNG's valuation, growth and risks.
DKNG cannot be valued on earnings, since its P/E is not meaningful: the company lost money over the last 12 months. On sales, though, the stock trades at 1.58 times, which is 16.8% below the sector median of 1.9. To put the size in context, DKNG has a market capitalisation of $10.2B and trailing earnings of -$0.37 per share.
The company is losing money, with a net margin of -2.68% and an operating margin of -4.72%. With a revenue decline of 4.60%, DKNG is 11.8 percentage points slower than the sector median of 7.2%. It reports a return on equity of -21.14%, below the sector median of 12.4%. The balance sheet rounds out the picture, with debt-to-equity of 3.36.
DKNG's analysts expect average EPS of $0.8829 for this fiscal year, a rise of 33.8%. For next year the average estimate is $1.70, growth of 92.1%.
A typical day for DKNG moves about 3.32%, and its beta against the S&P 500 is 1.61. While the price stays under its moving averages, the trend is a headwind for anyone holding the shares. The price is 44.48% below its 52-week high of $36.98. Over the last 18 months insiders sold $86.8M of stock and bought $3.2M. Insider sales are often planned ahead or made to cover taxes on vesting shares, so they tell less than open-market purchases would.
DKNG against the Consumer Cyclical sector
How DKNG compares with the median Consumer Cyclical stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, DKNG trades at 1.58x, -17% versus the sector average of 1.90x.
Return vs SPY: Since May 9, 2025, DKNG has lost 43.3% against a gain of 37.2% for SPY.
Performance against SPY
DKNG and the Consumer Cyclical sector fund over the same days.
Revenue and earnings
How much DKNG sells, and how much of it becomes profit.
Revenue growth: Revenue grew 27.0% in FY2025 to $6.1B, from $4.8B a year earlier.
Profit margin: The net margin was 0.1% in FY2025, up from -10.6% the year before.
Profitable: DKNG earned $3.7M in FY2025.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 49.2, in neutral territory.RSI above 50 ›
An RSI of 49.2 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of DKNG
The score, the reasoning behind it, and what could move the price next.
DraftKings Inc. (DKNG) is in a downtrend. At $20.53, the stock sits 17.01% below its 200-day average of $24.74 and 8.70% below its 50-day average of $22.49. Its place in the 52-week range is near the bottom: the price is 11.88% above the low of $18.35 and 44.48% below the high of $36.98. Both averages point the same way, with the 50-day sitting 9.10% below the 200-day.
The price is down over each of these periods: 6.55% over the past month, 10.07% over the past three months and 38.94% over the past year. The 14-day RSI of 49.2 is in the neutral zone, and the MACD line is negative.
Rating reaffirmed ›
Morgan Stanley kept its Overweight rating on October 19, 2026.
Source: Analyst action, Morgan Stanley, October 19, 2026
No risks flagged.
- Keep an eye on the two closest levels: the 50-day SMA at $22.49 sits above the price, while the 20-day EMA at $20.24 sits below it.
- A 14-day RSI of 49.2 is neutral, and the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum.
DKNG sits under both its 50-day ($22.49) and 200-day ($24.74) averages, and that is the reason the trend reads down. A climb back above the 50-day would be the first sign of repair, and that average is the closest level overhead, at $22.49.
Below the price, the 20-day EMA at $20.24 is the next marker. The 14-day RSI of 49.2 is in the neutral band, between 40 and 60.
Technical indicators
Momentum and trend for DKNG, from its daily closes.
As of October 22, 2026, with DKNG at $20.53, its 14-day RSI is 49.2 (neutral territory), its 50-day simple moving average is $22.49 and its 200-day is $24.74.
Calculated by CleaRank on daily closes as of October 22, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What DKNG moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 22, 2026, DKNG's 1-year correlation of daily returns is +0.35 with S&P 500 (SPY), +0.31 with Nasdaq 100 (QQQ), +0.09 with Bitcoin (BTC) and +0.01 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
31 of 37 analysts rate it a buy or strong buy, 5 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $31.00 is 51.0% above the price.More buy ratings than three months ago ›
31 of 37 rate it a buy now, against 29 of 36 three months ago.
DKNG Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 19, 2026 | Morgan Stanley | Maintains | Overweight |
| Oct 19, 2026 | Wells Fargo | Maintains | Overweight |
| Oct 12, 2026 | Citigroup | Maintains | Buy |
| Oct 8, 2026 | Susquehanna | Maintains | Positive |
| Oct 7, 2026 | Macquarie | Maintains | Outperform |
| Oct 7, 2026 | Guggenheim | Maintains | Buy |
As of October 22, 2026, 37 Wall Street analysts cover DKNG: 31 rate it a buy or strong buy, 5 a hold and 1 a sell or strong sell. Their 12-month price targets range from $20.00 to $76.00, with a median of $31.00, 51.0% above the price of $20.53.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
DKNG trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Short entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
DKNG moves about 3.3% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much DKNG tends to move, against the market and on its own.
The long record
DKNG's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
0/4Average daily move under 2% ›
The price has moved 3.32% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 85.7%, from March 2021 to May 2022; the price is still 71.3% below that peak.Most 1-year holds ended higher ›
56% of 1-year holding periods in the last 7 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in July 2019 is now worth $20,949, against $28,601 in the S&P 500 (SPY).
DKNG Drawdowns & Recovery
As of October 22, 2026, DKNG's worst peak-to-trough fall over the last 7 years with dividends reinvested was -85.7% (March 2021 to May 2022); it is still 71.3% below that peak, and 56% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into DKNG in July 2019 is worth now, against the same amount in the S&P 500.
Against the market: DKNG trailed the S&P 500 over this period: $20,949 against $28,601.
A $10,000 investment in DKNG in July 2019 would be worth about $20,949 today with dividends reinvested, compared with about $28,601 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to DKNG, and which have not.
Strongest month, November: an average of +12.41%, up in 6 of 7 years.
Weakest month, October: an average of -10.12%, up in 0 of 7 years.
This month, October: has averaged -10.12%, up in 0 of 7 years. Past seasonality does not repeat on schedule.
Over the last 8 years, DKNG's strongest calendar month has been November (average +12.41%, up in 6 of 7 years) and its weakest October (average -10.12%, up in 0 of 7 years).
Average return for each calendar month over the last 8 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in DKNG, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in DKNG today could grow to about $21,599 by 2036 in the base case, with a 90th-percentile outcome near $163,863 and a 10th-percentile outcome around $2,847. Projections are statistical simulations, not guarantees.
DKNG Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $27.94 for DKNG by 2030 in the base case, from $20.53 today (1.4x over 4 years). The 10th-percentile path ends near $7.75. These are outcomes of a Monte Carlo simulation run on DKNG's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $11.68 | $22.17 | $42.09 | |
| 2028 | $9.68 | $23.95 | $59.27 | |
| 2029 | $8.53 | $25.87 | $78.48 | |
| 2030 | $7.75 | $27.94 | $101 | |
| 2031 | $7.20 | $30.17 | $126 |
Method: a lognormal simulation of DKNG's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
DKNG insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $3.2M on the open market and sold $86.8M.
As of October 22, 2026, DKNG insiders reported 27 open-market sales worth $86.8M and 3 open-market purchases worth $3.2M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Jason Shand Robins
Chief Executive Officer
|
Grant | 12.0K | - |
| Sep 1, 2026 | Robert Stanton Dodge
Officer
|
Grant | 34.7K | - |
| Sep 1, 2026 | Alan Wayne Ellingson
Chief Financial Officer
|
Grant | 28.1K | - |
| Sep 1, 2026 | Paul Liberman
Officer and Director
|
Grant | 72.9K | - |
| Sep 1, 2026 | Jason Shand Robins
Chief Executive Officer
|
Grant | 126.6K | - |
| Aug 19, 2026 | Jocelyn Moore
Director
|
Sell | 10.8K | $258.8K |
| Aug 12, 2026 | Matthew Kalish
Director
|
Option | 383.5K | $1.8M |
| Jul 31, 2026 | Robert Stanton Dodge
Officer
|
Grant | 1.5K | - |
| Jul 31, 2026 | Alan Wayne Ellingson
Chief Financial Officer
|
Grant | 4.3K | - |
| Jul 1, 2026 | Robert Stanton Dodge
Officer
|
Grant | 1.5K | - |
| Jun 12, 2026 | Jason Shand Robins
Chief Executive Officer
|
Grant | 8.5K | - |
| Jun 11, 2026 | Robert Stanton Dodge
Officer
|
Sell | 62.5K | $1.9M |
| Jun 11, 2026 | Robert Stanton Dodge
Officer
|
Option | 62.5K | $184.4K |
| Jun 1, 2026 | Robert Stanton Dodge
Officer
|
Grant | 34.7K | - |
| Jun 1, 2026 | Alan Wayne Ellingson
Chief Financial Officer
|
Grant | 28.1K | - |
| Jun 1, 2026 | Paul Liberman
Officer and Director
|
Grant | 72.9K | - |
| Jun 1, 2026 | Jason Shand Robins
Chief Executive Officer
|
Grant | 126.6K | - |
| May 20, 2026 | Erik Bradbury
Officer
|
Sell | 862 | $21.8K |
| May 18, 2026 | Woodrow Levin
Director
|
Sell | 34.2K | $880.2K |
| May 12, 2026 | Woodrow Levin
Director
|
Grant | 5.6K | - |
| May 12, 2026 | Jocelyn Moore
Director
|
Grant | 5.6K | - |
| May 12, 2026 | Ryan R Moore
Director
|
Grant | 5.6K | - |
| May 12, 2026 | Valerie A Mosley
Director
|
Grant | 5.6K | - |
| May 12, 2026 | Steven Joseph Murray
Director
|
Grant | 5.6K | - |
| May 12, 2026 | Harry Evans Sloan
Director
|
Grant | 5.6K | - |
| May 12, 2026 | Marni M Walden
Director
|
Grant | 5.6K | - |
| May 12, 2026 | Gregory Westin Wendt
Director
|
Grant | 7.6K | - |
| May 1, 2026 | Robert Stanton Dodge
Officer
|
Grant | 1.5K | - |
| May 1, 2026 | Alan Wayne Ellingson
Chief Financial Officer
|
Grant | 4.3K | - |
| Apr 1, 2026 | Robert Stanton Dodge
Officer
|
Grant | 1.5K | - |
| Mar 13, 2026 | Jocelyn Moore
Director
|
Sell | 2.2K | $55.0K |
| Mar 11, 2026 | Paul Liberman
Officer and Director
|
Sell | 484.4K | $12.2M |
| Mar 11, 2026 | Paul Liberman
Officer and Director
|
Option | 484.4K | $305.2K |
| Mar 9, 2026 | Matthew Kalish
Officer and Director
|
Option | 273.5K | $899.8K |
| Mar 3, 2026 | Erik Bradbury
Officer
|
Sell | 2.9K | $70.8K |
| Feb 27, 2026 | Erik Bradbury
Officer
|
Grant | 8.0K | - |
| Feb 27, 2026 | Robert Stanton Dodge
Officer
|
Grant | 21.7K | - |
| Feb 27, 2026 | Alan Wayne Ellingson
Chief Financial Officer
|
Grant | 9.8K | - |
| Feb 27, 2026 | Matthew Kalish
Officer and Director
|
Grant | 39.7K | - |
| Feb 27, 2026 | Paul Liberman
Officer and Director
|
Grant | 39.7K | - |
| Feb 27, 2026 | Jason Robins
Chief Executive Officer
|
Grant | 67.9K | - |
| Feb 19, 2026 | Erik Bradbury
Officer
|
Sell | 7.3K | $163.5K |
| Feb 18, 2026 | Paul Liberman
Officer and Director
|
Option | 400.0K | $1.3M |
| Feb 18, 2026 | Paul Liberman
Officer and Director
|
Grant | 200.0K | - |
| Feb 17, 2026 | Harry Evans Sloan
Director
|
Buy | 100.0K | $2.2M |
| Feb 13, 2026 | Erik Bradbury
Officer
|
Grant | 43.9K | - |
| Feb 13, 2026 | Robert Stanton Dodge
Officer
|
Grant | 25.7K | - |
| Feb 13, 2026 | Alan Wayne Ellingson
Chief Financial Officer
|
Grant | 25.0K | - |
| Feb 13, 2026 | Matthew Kalish
Officer and Director
|
Grant | 51.5K | - |
| Feb 13, 2026 | Paul Liberman
Officer and Director
|
Grant | 51.5K | - |
| Feb 13, 2026 | Jason Robins
Chief Executive Officer
|
Grant | 87.5K | - |
| Feb 10, 2026 | Woodrow Levin
Director
|
Grant | 460 | - |
| Feb 10, 2026 | Jocelyn Moore
Director
|
Grant | 622 | - |
| Feb 10, 2026 | Ryan R Moore
Director
|
Grant | 668 | - |
| Feb 10, 2026 | Valerie A Mosley
Director
|
Grant | 553 | - |
| Feb 10, 2026 | Steven Joseph Murray
Director
|
Grant | 760 | - |
| Feb 10, 2026 | Harry Evans Sloan
Director
|
Grant | 507 | - |
| Feb 10, 2026 | Marni M Walden
Director
|
Grant | 691 | - |
| Feb 10, 2026 | Gregory Westin Wendt
Director
|
Grant | 345 | - |
| Feb 9, 2026 | Robert Stanton Dodge
Officer
|
Grant | 14.2K | - |
| Feb 9, 2026 | Matthew Kalish
Officer and Director
|
Grant | 28.3K | - |
| Feb 9, 2026 | Paul Liberman
Officer and Director
|
Grant | 28.3K | - |
| Feb 9, 2026 | Jason Robins
Chief Executive Officer
|
Grant | 38.2K | - |
| Jan 30, 2026 | Robert Stanton Dodge
Officer
|
Grant | 808 | - |
| Jan 30, 2026 | Alan Wayne Ellingson
Chief Financial Officer
|
Grant | 4.3K | - |
| Jan 20, 2026 | Robert Stanton Dodge
Officer
|
Sell | 52.8K | $1.7M |
| Jan 20, 2026 | Robert Stanton Dodge
Officer
|
Option | 40.1K | $118.2K |
| Dec 31, 2025 | Robert Stanton Dodge
Officer
|
Grant | 808 | - |
| Dec 10, 2025 | Matthew Kalish
Officer and Director
|
Grant | 3.0M | - |
| Dec 9, 2025 | Paul Liberman
Officer and Director
|
Grant | 75.0K | - |
| Dec 1, 2025 | Robert Stanton Dodge
Officer
|
Sell | 52.8K | $1.8M |
| Dec 1, 2025 | Erik Bradbury
Officer
|
Grant | 3.8K | - |
| Dec 1, 2025 | Robert Stanton Dodge
Officer
|
Option | 66.0K | $130.9K |
| Dec 1, 2025 | Alan Wayne Ellingson
Chief Financial Officer
|
Grant | 9.8K | - |
| Dec 1, 2025 | Matthew Kalish
Officer and Director
|
Grant | 39.7K | - |
| Dec 1, 2025 | Paul Liberman
Officer and Director
|
Grant | 39.7K | - |
| Dec 1, 2025 | Jason Robins
Chief Executive Officer
|
Option | 68.0K | $33 |
| Nov 20, 2025 | Paul Liberman
Officer and Director
|
Option | 89.2K | $293.3K |
| Nov 20, 2025 | Jason Robins
Chief Executive Officer
|
Grant | 13.7K | - |
| Nov 14, 2025 | Alan Wayne Ellingson
Chief Financial Officer
|
Sell | 8.4K | $246.1K |
| Nov 11, 2025 | Harry Evans Sloan
Director
|
Buy | 25.0K | $757.5K |
| Nov 11, 2025 | Gregory Westin Wendt
Director
|
Buy | 10.0K | $302.7K |
| Nov 7, 2025 | Robert Stanton Dodge
Officer
|
Grant | 14.2K | - |
| Nov 7, 2025 | Matthew Kalish
Officer and Director
|
Grant | 28.3K | - |
| Nov 7, 2025 | Paul Liberman
Officer and Director
|
Grant | 28.3K | - |
| Nov 7, 2025 | Jason Robins
Chief Executive Officer
|
Grant | 38.2K | - |
| Nov 6, 2025 | Robert Stanton Dodge
Officer
|
Sell | 52.8K | $1.5M |
| Nov 6, 2025 | Robert Stanton Dodge
Officer
|
Option | 52.8K | $155.7K |
| Nov 6, 2025 | Woodrow Levin
Director
|
Grant | 446 | - |
| Nov 6, 2025 | Jocelyn Moore
Director
|
Grant | 603 | - |
| Nov 6, 2025 | Ryan R Moore
Director
|
Grant | 647 | - |
| Nov 6, 2025 | Valerie A Mosley
Director
|
Grant | 536 | - |
| Nov 6, 2025 | Steven Joseph Murray
Director
|
Grant | 737 | - |
| Nov 6, 2025 | Harry Evans Sloan
Director
|
Grant | 491 | - |
| Nov 6, 2025 | Marni M Walden
Director
|
Grant | 670 | - |
| Oct 31, 2025 | Robert Stanton Dodge
Officer
|
Grant | 808 | - |
| Oct 31, 2025 | Alan Wayne Ellingson
Chief Financial Officer
|
Grant | 4.3K | - |
| Oct 17, 2025 | Robert Stanton Dodge
Officer
|
Sell | 52.8K | $1.8M |
| Oct 17, 2025 | Robert Stanton Dodge
Officer
|
Option | 40.1K | $118.4K |
| Oct 1, 2025 | Robert Stanton Dodge
Officer
|
Grant | 808 | - |
| Sep 12, 2025 | Matthew Kalish
Officer and Director
|
Grant | 21.3K | - |
| Sep 2, 2025 | Robert Stanton Dodge
Officer
|
Sell | 105.6K | $5.0M |
| Sep 2, 2025 | Robert Stanton Dodge
Officer
|
Option | 119.3K | $287.9K |
| Aug 29, 2025 | Erik Bradbury
Officer
|
Grant | 3.8K | - |
| Aug 29, 2025 | Alan Wayne Ellingson
Chief Financial Officer
|
Grant | 9.8K | - |
| Aug 29, 2025 | Matthew Kalish
Officer and Director
|
Grant | 39.7K | - |
| Aug 29, 2025 | Paul Liberman
Officer and Director
|
Grant | 39.7K | - |
| Aug 29, 2025 | Jason Robins
Chief Executive Officer
|
Grant | 67.9K | - |
| Aug 25, 2025 | Jason Robins
Chief Executive Officer
|
Grant | 10.0K | - |
| Aug 21, 2025 | Ryan R Moore
Director
|
Sell | 76.4K | $3.5M |
| Aug 19, 2025 | Alan Wayne Ellingson
Chief Financial Officer
|
Sell | 44.7K | $2.0M |
| Aug 15, 2025 | Alan Wayne Ellingson
Chief Financial Officer
|
Sell | 5.7K | $249.2K |
| Aug 13, 2025 | Jocelyn Moore
Director
|
Sell | 4.9K | $210.0K |
| Aug 12, 2025 | Matthew Kalish
Officer and Director
|
Sell | 420.0K | $18.0M |
| Aug 12, 2025 | Matthew Kalish
Officer and Director
|
Option | 448.3K | $1.4M |
| Aug 8, 2025 | Robert Stanton Dodge
Officer
|
Grant | 14.2K | - |
| Aug 8, 2025 | Paul Liberman
Officer and Director
|
Grant | 28.3K | - |
| Aug 8, 2025 | Jason Robins
Chief Executive Officer
|
Grant | 38.2K | - |
| Aug 5, 2025 | Robert Stanton Dodge
Officer
|
Sell | 105.6K | $4.7M |
| Aug 5, 2025 | Robert Stanton Dodge
Officer
|
Option | 105.1K | $332.6K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 22, 2026.
